198 related articles for article (PubMed ID: 32542023)
1. The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study.
Douwes RM; Gomes-Neto AW; Eisenga MF; Van Loon E; Schutten JC; Gans ROB; Naesens M; van den Berg E; Sprangers B; Berger SP; Navis G; Blokzijl H; Meijers B; Bakker SJL; Kuypers D
PLoS Med; 2020 Jun; 17(6):e1003140. PubMed ID: 32542023
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients.
Lyu B; Jorgenson MR; Hansen KE; Djamali A; Astor BC
Transplantation; 2020 Dec; 104(12):2609-2615. PubMed ID: 32058466
[TBL] [Abstract][Full Text] [Related]
3. Type of proton-pump inhibitor and risk of iron deficiency in kidney transplant recipients - results from the TransplantLines Biobank and Cohort Study.
Douwes RM; Vinke JSJ; Gomes-Neto AW; Ayerdem G; van Hassel G; Berger SP; Touw DJ; Blokzijl H; Bakker SJL; de Borst MH; Eisenga MF
Transpl Int; 2021 Nov; 34(11):2305-2316. PubMed ID: 34519109
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study.
Knobbe TJ; Kremer D; Douwes RM; Eisenga MF; Gomes-Neto AW; Annema C; Swarte JC; Klont F; Navis G; Berger SP; Bakker SJL;
Am J Kidney Dis; 2023 Aug; 82(2):189-201.e1. PubMed ID: 36801431
[TBL] [Abstract][Full Text] [Related]
5. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence.
Ben-Eltriki M; Green CJ; Maclure M; Musini V; Bassett KL; Wright JM
Pharmacol Res Perspect; 2020 Oct; 8(5):e00651. PubMed ID: 32996701
[TBL] [Abstract][Full Text] [Related]
6. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
7. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
8. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children.
Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
JAMA Pediatr; 2021 Apr; 175(4):394-403. PubMed ID: 33555324
[TBL] [Abstract][Full Text] [Related]
9. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
10. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
11. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study.
Schjerning Olsen AM; Lindhardsen J; Gislason GH; McGettigan P; Hlatky MA; Fosbøl E; Køber L; Torp-Pedersen C; Lamberts M
BMJ; 2015 Oct; 351():h5096. PubMed ID: 26481405
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events.
Fortuna LA; Pawloski PA; Parker ED; Trower NK; Kottke TE
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):13-9. PubMed ID: 27533057
[TBL] [Abstract][Full Text] [Related]
13. Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients.
Douwes RM; Gomes-Neto AW; Schutten JC; van den Berg E; de Borst MH; Berger SP; Touw DJ; Hak E; Blokzijl H; Navis G; Bakker SJL
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817776
[TBL] [Abstract][Full Text] [Related]
14. Plasma endotrophin, reflecting tissue fibrosis, is associated with graft failure and mortality in KTRs: results from two prospective cohort studies.
Kremer D; Alkaff FF; Post A; Knobbe TJ; Tepel M; Thaunat O; Berger SP; van den Born J; Genovese F; Karsdal MA; Rasmussen DGK; Bakker SJL
Nephrol Dial Transplant; 2023 Mar; 38(4):1041-1052. PubMed ID: 36535643
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Summereder C; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
PLoS One; 2014; 9(11):e110503. PubMed ID: 25369194
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitor usage is associated with higher all-cause mortality and CV events in peritoneal dialysis patients.
Zeng Y; Liu L; Zhu L; Zhan X; Peng F; Feng X; Zhou Q; Zhang Y; Wang Z; Liang J; Li J; Wen Y
Ren Fail; 2022 Dec; 44(1):407-414. PubMed ID: 35236240
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome-related dietary pattern and risk of mortality in kidney transplant recipients.
Cai Q; Osté MCJ; Gomes-Neto AW; Dekker LH; Borgonjen-van den Berg KJ; Geleijnse JM; Bakker SJL; de Borst MH; Navis GJ
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1129-1136. PubMed ID: 33618925
[TBL] [Abstract][Full Text] [Related]
18. Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.
Ahn N; Wawro N; Baumeister SE; Nolde M; Gerlach R; Tauscher M; Günter A; Güntner F; Rückert-Eheberg IM; Meisinger C; Linseisen J
Drugs Aging; 2023 Jul; 40(7):653-663. PubMed ID: 37178361
[TBL] [Abstract][Full Text] [Related]
19. Chronic Use of Proton-Pump Inhibitors and Iron Status in Renal Transplant Recipients.
Douwes RM; Gomes-Neto AW; Eisenga MF; Vinke JSJ; de Borst MH; van den Berg E; Berger SP; Touw DJ; Hak E; Blokzijl H; Navis G; Bakker SJL
J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31484461
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
